Galmed Pharmaceuticals Ltd.

EOCN · Nasdaq · Israel

Share price · EOCN

$2.20+1.64 (+292.45%) 3M

close as of 2026-11-18 · 24h delayed · vol 25K (3.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when EOCN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 19 Aug 2026+751.5%
  2. 1 Jul 2026+16.4%
  3. 11 Jun 2026+17.3%

    Nothing announced by EOCN that day or the session before.

  4. 8 Jun 2026-32.6%
  5. 9 Apr 2026+26.2%
  6. 27 Mar 2026-14.2%

    Nothing announced by EOCN that day or the session before.

  7. 25 Feb 2026+15.1%

    Nothing announced by EOCN that day or the session before.

  8. 10 Dec 2025-8.6%

    Nothing announced by EOCN that day or the session before.

  9. 3 Dec 2025+11.6%

    Nothing announced by EOCN that day or the session before.

  10. 26 Nov 2025+12.4%

Share of unusual movement by asset

For each asset, the share of EOCN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Aramchol
events and moves
190%
Other company news (earnings, financing, releases naming no asset)—84%
Sessions with no dated event—16%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Stearoyl-CoA desaturase 1 (SCD1)
MASH / NASH

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
November 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-11-25 · Fiscal period ending 2026-09-30
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (7)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$1.8M$2.9M+ $5.9M short-term inv.$2.7Mreport ↗
View 6 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3—$1.1M$3.3M+ $8.2M short-term inv.$1.9M-$1.9M operating cash flowreport ↗
2025-Q2—$1.1M$5.0M+ $8.1M short-term inv.$2.5Mreport ↗
2024-Q3—$0.7M—$1.9M-$1.1M operating cash flowreport ↗
2024-Q2—$0.5M$1.8M+ $5.9M short-term inv.$1.1Mreport ↗
2023-Q2—$0.8M$1.0M+ $7.6M short-term inv.$1.6Mreport ↗
2022-Q2—$2.6M$2.0M+ $20M short-term inv.$3.7Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$4.9M$4.0M+ $7.0M short-term inv.$2.6M-$6.3M operating cash flowreport ↗

Galmed Pharmaceuticals did not disclose revenue for fiscal year 2025. R&D spend was $4.87M, up 63.4% YoY, with cash and equivalents of $3.99M. The company reported a net loss of $10.31M and a quarterly net burn of $10.31M.

The company is advancing Aramchol for oncological indications outside NASH and fibrosis and is evaluating cardiometabolic and other innovative product candidates. It discontinued the open-label part of the ARMOR Study and does not currently expect to initiate the second part; management also noted substantial doubt about the company’s ability to continue as a going concern, while estimating that current cash supports operations for more than 12 months.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$3.0M$4.7M+ $7.2M short-term inv.$1.9M-$5.9M operating cash flowreport ↗
2023-FY—$3.6M$2.9M+ $7.5M short-term inv.$1.7M-$6.1M operating cash flowreport ↗
2022-FY—$13M$2.0M+ $12M short-term inv.$4.5M-$19M operating cash flowreport ↗
2021-FY—$27M$2.9M+ $32M short-term inv.$8.1M-$33M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

No Form 4 transactions on file in the stored window.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 16 reporting institutions held 0.1M shares ($71K).

#InstitutionSharesValue
1TWO SIGMA INVESTMENTS, LP80,177$39K
2XTX Topco Ltd22,396$11K
3JANE STREET GROUP, LLC16,445$8K
4TWO SIGMA SECURITIES, LLC11,971$6K
5CITADEL ADVISORS LLC11,382$6K
6UBS Group AG2,546$1K
7BNP PARIBAS FINANCIAL MARKETS600$294
8MORGAN STANLEY157$77
9WELLS FARGO & COMPANY/MN43$21
10SBI Securities Co., Ltd.16$8
11Federation des caisses Desjardins du Quebec14$7
12OSAIC HOLDINGS, INC.5$2
13Allworth Financial LP2$1
14ELEVATION WEALTH PARTNERS, LLC1$1
15Dogwood Wealth Management LLC1$0